Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03801629 · ClinicalTrials.gov registry record · Phase 1
Neuroimmune Effects of Opioid Administration
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT03801629 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 10 participants.
The verdict
NCT03801629, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
Preclinical research indicates acute opioid administration evokes an immune response in the periphery and brain. Here, we will translate those preclinical findings to healthy human volunteers and quantify the neuroimmune response to a morphine challenge using positron emission tomography (PET) imaging with \[11C\]PBR28.
Interventions
- DRUG High Morphine Dose
- DRUG Low Morphine Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-09-12 |
| Est. Completion | 2021-03-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03801629
The ClinicalTrials.gov registry entry for NCT03801629 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which High Morphine Dose is the first listed.
NCT03801629 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03801629 about?
NCT03801629 is a clinical study titled "Neuroimmune Effects of Opioid Administration". Preclinical research indicates acute opioid administration evokes an immune response in the periphery and brain. Here, we will translate those preclinical findings to healthy human volunteers and quantify the neuroimmune response to a morphine challenge using positron emission tomography (PET) imagi...
What is the current status of trial NCT03801629?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2019-09-12. Estimated completion is 2021-03-10.
What interventions are being tested in trial NCT03801629?
The interventions under investigation include: High Morphine Dose (DRUG), Low Morphine Dose (DRUG).
Who is sponsoring clinical trial NCT03801629?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.